LiDCO (AIM: LID), the hemodynamic monitoring company, announces that the Board has yesterday, 19th April 2017, finalised a grant of options ('Options') to Mr Sassone, CEO, to subscribe for new ordinary shares of 0.5p each ('Ordinary Shares').
Option type
Number of shares over which options granted
Total number of options held post grant
Percentage of issued share capital under option
Matt Sassone
EMI
3,448,262
3,448,262
1.4%
Unapproved
3,147,342
3,147,342
1.3%
Total
6,595,604
6,595,604
2.7%
The above Options vest and may be exercised from between fourteen months and three years from grant if certain share price hurdles are met. The Options are exercisable over a range of periods at 0.5 pence per Ordinary Share, subject to the Company's share price averaging above a number of hurdle rates. Expiry dates range from April 2022 to June 2025. The hurdle rates were in part set with regard to the placing price of 6p in December 2016 and are between 8p and 15p. Full details are given in the Company's report and accounts (Directors' remuneration report) which are available on the Company's website.
Simultaneous with this grant, 4,395,604 options have lapsed and been cancelled. The total number of shares under option following these grants is therefore 14,990,087 representing 6.1% of the issued share capital.
The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
1.
Details of the person discharging managerial responsibilities/person closely associated
a)
Name:
Matt Sassone
2.
Reason for the notification
a)
Position/status:
Chief Executive Officer
b)
Initial notification/Amendment:
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name:
LiDCO Group Plc
b)
LEI:
n/a
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument:
Identification code:
Ordinary Shares of 0.5p nominal
GB0030546849
b)
Nature of the transaction:
Price(s)
Volume(s)
0.5p
6,595,604
c)
Price(s) and volume(s):
Single transaction as in 4 c) above
Price(s)
Volume(s)
0.5p
6,595,604
e)
Date of the transaction:
19/04/17
f)
Place of the transaction:
London Stock Exchange, AIM (XLON)
LiDCO Group Plc
www.lidco.com
Matt Sassone (CEO)
Tel: +44 (0)20 7749 1500
finnCap
Tel: +44 (0)20 7600 1658
Geoff Nash / Emily Watts (Corporate Finance)
Stephen Norcross (Corporate Broking)
Walbrook PR Ltd
Tel: 020 7933 8780 or lidco@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
Lianne Cawthorne
Mob: 07584 391 303
Back to News Releases
LIDCO Group plc published this content on 20 April 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 20 April 2017 16:42:16 UTC.
Original documenthttp://www.lidco.com/investor/news/2017/20-04-17.php
Public permalinkhttp://www.publicnow.com/view/8FE211BC97DE7EE2F0DB0892994F8D6CF3786C6F
Lidco Group Ltd, formerly LiDCO Group Plc, is a United Kingdom-based supplier of non-invasive and minimally invasive hemodynamic monitoring equipment to hospitals. The Company is engaged in the development, manufacture and sale of cardiac monitoring equipment. It operates in the segment of supply of monitors, consumables and support services associated with the use of its cardiac monitoring equipment. The Company's products include LiDCOplus, a computer-based platform monitor; LiDCOrapid, a cardiac output monitor; LiDCOview, a graphical display, and LiDCOunity, which is its hemodynamic monitor. Its LiDCOrapid is designed for multi-parameter monitoring of both depth of anesthesia and fluids. Its products are used in the treatment of high-risk patients in both critical care units and in the operating theatre. They monitor the amount of blood flowing around the body helping clinicians and nurses to ensure that organs are kept perfused with oxygenated blood.